Tasso di persistenza in terapia e fattori predittivi di sopravvivenza degli inibitori dell’interleuchina-1 nell’artrite idiopatica giovanile a esordio sistemico

Translated title of the contribution: [Autom. eng. transl.] Therapy persistence rate and predictive survival factors of interleukin-1 inhibitors in systemic-onset juvenile idiopathic arthritis

Donato Rigante, C Gaggiano, J Sota, A Insalaco, R Cimaz, M Alessio, M Cattalini, R Gallizzi, M Maggio, G Lopalco, F La Torre, C Fabiani, M Pardeo, A Olivieri, P Sfriso, C Salvarani, S Grosso, C Bracaglia, F De Benedetti, L Cantarini

Research output: Contribution to journalMeeting Abstract

Abstract

[Autom. eng. transl.] The introduction of biological drugs has revolutionized the therapeutic approach in Idiopathic Juvenile Systemic Arthritis (SoJIA), modifying the natural history of this disease and improving its overall outcome. The main objective of the study was to analyze the persistence rate in therapy (DRR) of Interleukin (IL) -1 inhibitors in patients with SoJIA. Secondary objectives of the study were: (1) to explore the influence of the biological treatment line, of adverse events, of the specific anti-IL-1 agent and of the treatment with disease modifying anti-rheumatic drugs (cDMARDs) on DRR; (2) identify any predictive factors associated with abandoning the therapy. Demographic, clinical and therapeutic data relating to patients with SoJIA treated with anakinra and canakinumab in 15 Italian centers were collected retrospectively and analyzed. 77 patients were enrolled, corresponding to 86 treatment regimens. The cumulative DRR of IL-1 inhibitors was found to be at 12-, 24-, 48- and 60-month follow-up respectively 79.9, 59.5, 53.5 and 53.5%. No statistically significant difference was found by stratifying for anakinra and canakinumab (p = 0.056) and between patients receiving monotherapy and those being treated with cDMARDs (p = 0.058). On the contrary, significant differences were identified between the group of biologic-naive patients and that of patients previously treated with other biological therapies (p = 0.038) and in relation to the occurrence of adverse events (AE) during therapy (p = 0.04). The study revealed the extraordinary efficacy of IL-1 antagonists in the management of patients with SoJIA.
Translated title of the contribution[Autom. eng. transl.] Therapy persistence rate and predictive survival factors of interleukin-1 inhibitors in systemic-onset juvenile idiopathic arthritis
Original languageItalian
Pages (from-to)70-70
Number of pages1
JournalAtti del 75° Congresso Italiano di Pediatria, 29 maggio-1 giugno 2019, Bologna
Publication statusPublished - 2019

Keywords

  • Artrite idiopatica giovanile

Fingerprint Dive into the research topics of '[Autom. eng. transl.] Therapy persistence rate and predictive survival factors of interleukin-1 inhibitors in systemic-onset juvenile idiopathic arthritis'. Together they form a unique fingerprint.

Cite this